About Advanced Micro Devices, Inc. - Common Stock (AMD)
Advanced Micro Devices is a leading global semiconductor company that designs and manufactures computing and graphics solutions for a wide range of applications. The company is known for its innovative microprocessors, graphics cards, and system-on-chip products, which are used in personal computers, servers, and embedded systems. AMD focuses on high-performance computing, gaming, and data center markets, offering advanced technologies that compete with those of other major players in the industry. By delivering cutting-edge products that push the boundaries of processing power and efficiency, AMD plays a critical role in driving technological advancements and enhancing user experiences across various platforms. Read More
Despite AI safety concerns triggering a sector selloff, Q2 backlogs and CapEx data show infrastructure demand accelerating, with NVIDIA and AMD positioned to benefit as inference adoption grows.
Qualcomm shares have rallied 30% since August but still carry a low valuation, as analysts weigh growth in AI data centers and automotive against Apple's move to in-house modem chips.
Micron's bullish chart trends, analyst price targets, and tight HBM capacity through 2027-2028 point to sustained pricing power and potential further upside for MU stock.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Nutanix (NASDAQ:NTNX) is positioning itself as a broader cloud-platform provider rather than solely a hyperconverged infrastructure, or HCI, company, as it pursues growth through external storage, public cloud, Kubernetes, database management and enterprise artificial intelligence offerings.
Chief
Hewlett Packard Enterprise (NYSE:HPE) Chief Strategy Officer Shannon Cross said the company is seeing strong demand across networking, storage and traditional servers, while supply availability and order conversion remain key priorities as it targets growth in fiscal 2027.
Speaking at the Goldman S
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.
